Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-27

once again a very vague, opaque, noncommittal piece of communication.

you guys are hopeless - top to bottom.

”we are confident that the study objectives are being met and that we can now begin to move ahead with the next phase of clinical investigations.”

so have the trials been successful?
are you beginning pivotal trials?
what does ‘begin to move ahead’ mean?

no wonder the market has no confidence in you.

you can’t fill a trial
you can’t meet timelines
you can’t communicate clearly

I hope if and when you present a submission to the FDA that you communicate a lot clearer and with a lot more specificity than the fluffy tripe you dish up to the market.

get your act together FFS.

you’ve had enough practice.

you seem way to comfortable with failure and mediocrity.